Based on the differential downstream gene expression profiles in our transcriptomic data for ALL and AML, we infer that these benefits from FLT3 inhibitors may be attributed to more comprehensive mechanisms involving the activation of downstream signaling pathways. Here, FLT3 is linked to acute myeloid leukemia.